Completed
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
2026-525590-40-00· Phase 1· Viiv Healthcare UK Limited· Source
Completed
A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167
2026-526096-31-00· Phase 1· Corteria Pharmaceuticals· Source
Active, not recruiting
A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease
NCT07495813· Phase 1· Hoffmann-La Roche· Source
Completed
A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
2025-524310-28-00· Phase 1· Quralis Corp.· Source
Completed
A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.
2025-523791-24-00· Phase 1· Immunic AG· Source
Completed
A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants
2025-523430-14-00· Phase 1· Janssen Cilag International· Source
Completed
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
2025-522368-34-00· Phase 1· Muna Therapeutics ApS· Source
Completed
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects
2025-521754-41-00· Phase 1· Immunic AG· Source
Completed
A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants
2024-518696-65-00· Phase 1· Pfizer Inc.· Source
Completed
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults
2025-521073-13-00· Phase 1· Sanofi-Aventis Recherche & Developpement· Source
Completed
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.
2024-510856-11-00· Phase 1· Bayer AG· Source
Completed
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE PHASE 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILE OF RES-010 IN HEALTHY, OVERWEIGHT, AND MODERATELY OBESE SUBJECTS
2024-514871-17-00· Phase 1· Resalis Therapeutics S.r.l.· Source
Completed
A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin
NCT06625307· Phase 1· Novo Nordisk A/S· Source
Completed
A study in healthy men to learn about how the body absorbs, processes, and removes radioactively labeled BAY 3283142
2024-510765-42-00· Phase 1· Bayer AG· Source
Completed
A Phase 1, Open-Label, Multiple-Part Trial to Evaluate the Drug-Drug Interaction Potential of PRAX-628 in Healthy Participants
2024-514426-23-01· Phase 1· Praxis Precision Medicines Inc.· Source
Completed
A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants
2023-507959-29-00· Phase 1· Novartis Pharma AG· Source
Completed
A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497
2023-508371-36-00· Phase 1· Pfizer Inc.· Source
Completed
A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DIFFERENT HYDROMETHYLTHIONINE MESYLATE (HMTM) TABLET FORMULATIONS AND STRENGTHS IN HEALTHY ADULT SUBJECTS.
2023-507661-26-00· Phase 1· Taurx Therapeutics Limited· Source
Completed
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.
2023-507074-40-00· Phase 1· Pfizer Inc.· Source
Completed
First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations.
2023-509158-68-00· Phase 1· Vanqua Bio Inc.· Source
Completed
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
NCT06221475· Phase 1· Bayer· Source
Completed
A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure (CHF)
2023-508543-42-00· Phase 1· Corteria Pharmaceuticals· Source
Completed
A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part
2023-505542-26-00· Phase 1· Novartis Pharma AG· Source
Completed
Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969
NCT06066099· Phase 1· Acesion Pharma· Source
Completed
Safety and Tolerability of AC01 in patients with heart failure
2022-500347-20-00· Phase 1/2· Anacardio AB· Source